Ascelia is an oncology-dedicated drug development company located in Malmö, Sweden, focused on the development of novel drugs to improve the life expectancy and quality of life for people living with cancer. Ascelia´s strategy is to develop and make available to patients a portfolio of differentiated, underappreciated and de-risked product candidates addressing unmet medical needs in cancer and cancer-related diseases. Ascelia is fully focused on two clinical-stage product candidates under development: Mangoral and Oncoral.
How many staff members are on the team currently & do you find it difficult to find quality local and international staff?
We are currently six persons in Ascelia Pharma, but we are expanding and will grow the staff with a few more persons shortly. Being a company located in Malmö we have a solid recruiting base from both sides of Öresund and the pharma industry has a strong foothold in both regions. This advantage is already visible in our current staff, which is mixed between Swedes and Danes. Consequently, we have so far not experienced difficulties in attracting high quality staff.
Do any of the staff and or management team hold any shares within the company?
All senior management members hold shares in Ascelia Pharma.
During your time at the company, what's been your greatest achievement thus far?
The recently completed IPO on Nasdaq Stockholm (main market) was major achievement and provided us with full financing of Mangoral for completing the last clinical phase (Phase III). The substantially oversubscribed IPO illustrated the attractiveness of our business case with a clear development path for both Mangoral and Oncoral. Unlike many other biotech companies, our lead candidate Mangoral is also at a very advanced stage with only one-and-a-half years from having final Phase III results.
What is your medium to long-term goal & has it been consistent for some time?
Our company DNA is to develop drugs that target a clear unmet medical need with an established mode of action as well as having a potential for global leadership position. Both our drug candidates Mangoral and Oncoral fulfil these criteria. When we in the future will look to acquire additional drug candidates these criteria will remain and thus, we keep our goals consistent.
Please share with us your favourite memory and or event since you joined the company?
Our X-factor is that we find niches in the pharmaceutical market, which is currently unserved and where there a clear gap to fill for our differentiated products. Our staff of very senior pharmaceutical professionals then develop the products through the clinical stages.